公开(公告)号：US20140348942A1

公开(公告)日：2014-11-27

申请号：US14124286

申请日：2012-06-08

Applicant: Mark G. Currie ,  Daniel P. Zimmer ,  Angelika Fretzen ,  Marco Kassler ,  Brian M. Cali

Inventor： Mark G. Currie ,  Daniel P. Zimmer ,  Angelika Fretzen ,  Marco Kassler ,  Brian M. Cali

IPC: C07K7/08 ,  A61K45/06 ,  A61K38/10

CPC classification number: C07K7/08 ,  A61K38/10 ,  A61K38/51 ,  A61K45/06

Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (IBD), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (BPH), pain, salt retention or fluid retention.

Abstract translation: 本发明提供了治疗下消化道疾病的药物组合物和方法，包括炎症性肠病（IBD），憩室炎，结肠癌，炎症性疾病，肥胖，充血性心力衰竭，良性前列腺增生（BPH），疼痛，盐滞留或流体 保留。

公开(公告)号：US20120136065A1

公开(公告)日：2012-05-31

申请号：US13365565

申请日：2012-02-03

Applicant: Thomas P. JERUSSI ,  Qun Kevin FANG ,  Mark G. CURRIE

Inventor： Thomas P. JERUSSI ,  Qun Kevin FANG ,  Mark G. CURRIE

IPC: A61K31/135 ,  A61P25/28

CPC classification number: A61K31/135 ,  C07B2200/07 ,  C07C211/42 ,  C07C2602/10

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract translation: 用（1R，4S） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺处理CNS障碍; 和（1S，4R） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺。 还公开了制备4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺的方法。 该方法包括制备N- [4-（3,4-二氯苯基）-1,2,3,4-四氢萘-1-基]甲酰胺的全部四种异构体，它们也是有用的。

公开(公告)号：US20120088902A1

公开(公告)日：2012-04-12

申请号：US12306788

申请日：2007-06-27

Applicant: Mark G. Currie ,  Daniel P. Zimmer

Inventor： Mark G. Currie ,  Daniel P. Zimmer

IPC: C07K14/00 ,  C07K7/08 ,  C07K7/06

CPC classification number: C07K14/4705 ,  A61K38/00

Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders and disorders and conditions associated with excess fluid and/or salt retention as well as other conditions and disorders are described. The compositions feature polypeptides that activate the guanylate cyclase C (GC-C) receptor.

公开(公告)号：US08101579B2

公开(公告)日：2012-01-24

申请号：US12568107

申请日：2009-09-28

Applicant: Mark G. Currie ,  Shalina Mahajan-Miklos ,  Li Jing Sun

Inventor： Mark G. Currie ,  Shalina Mahajan-Miklos ,  Li Jing Sun

IPC: A61K38/10 ,  A61K31/74

CPC classification number: C07K7/08 ,  A61K38/00

Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

Abstract translation: 用于治疗IBS和其他胃肠道疾病和病症的组合物和相关方法（例如，胃肠动力障碍，功能性胃肠道疾病，胃食管反流病（GERD），十二指肠胃反流，克罗恩病，溃疡性结肠炎，炎性肠病，功能性胃灼热，消化不良（包括 功能性消化不良或非溃疡性消化不良），胃轻瘫，慢性肠假性梗阻（或结肠假性梗阻）以及与便秘相关的疾病和病症，例如与使用阿片类止痛药相关的便秘，手术后便秘和与神经性疾病相关的便秘 描述了其它条件和病症，组合物具有激活鸟苷酸环化酶C（GC-C）受体的肽。

公开(公告)号：US08088935B2

公开(公告)日：2012-01-03

申请号：US10587054

申请日：2004-12-23

Applicant: James Pearson ,  John J. Talley ,  Mark G. Currie

Inventor： James Pearson ,  John J. Talley ,  Mark G. Currie

IPC: C07D311/22 ,  A61K31/353

CPC classification number: C07D491/04 ,  A61K31/353 ,  A61K31/4741 ,  A61K31/506 ,  C07D311/24 ,  C07D405/14 ,  C07D409/14

Abstract: Compounds and methods for the treatment of asthma are disclosed. The methods involve mast cell stabilization together with selective inhibition of iNOS. The compounds are combinations of a mast cell inhibiting moiety and an inhibitor of iNOS. An example is:

Abstract translation: 公开了治疗哮喘的化合物和方法。 该方法涉及肥大细胞稳定化以及iNOS的选择性抑制。 化合物是肥大细胞抑制部分和iNOS抑制剂的组合。 一个例子是：

公开(公告)号：US20110160225A1

公开(公告)日：2011-06-30

申请号：US12950283

申请日：2010-11-19

Applicant: Mark G. Currie ,  John Jeffrey Talley ,  Brian Cali

Inventor： Mark G. Currie ,  John Jeffrey Talley ,  Brian Cali

IPC: A61K31/496 ,  C07C203/04 ,  A61K31/21 ,  A61K31/24 ,  C07C69/716 ,  A61K31/216 ,  C07D263/28 ,  A61K31/421 ,  C07D207/22 ,  A61K31/40 ,  C07D403/04 ,  C07D239/42 ,  A61K31/505 ,  C07D209/24 ,  A61K31/405 ,  C07D403/12 ,  A61K31/41 ,  C07D403/14 ,  A61P3/06 ,  A61P3/10

CPC classification number: C07D257/06 ,  C07C69/712 ,  C07C69/732 ,  C07C203/04 ,  C07C235/30 ,  C07C259/06 ,  C07C279/12 ,  C07C279/14 ,  C07C279/22 ,  C07C281/16 ,  C07C291/02 ,  C07C2602/10 ,  C07C2602/28 ,  C07D207/22 ,  C07D207/34 ,  C07D209/24 ,  C07D239/42 ,  C07D263/28 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12

Abstract: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors.

Abstract translation: 本文公开了用于治疗或预防与脂质代谢相关的多种病症和病症的新型组合物和方法。 所述方法通常包括向有需要的患者施用治疗有效量的药物组合物，其包含一种或多种纤维酸或他汀类衍生物组合物，或与一种或多种脂质改变剂和/或PDE抑制剂组合。

公开(公告)号：US20110129433A1

公开(公告)日：2011-06-02

申请号：US13000679

申请日：2009-06-26

Applicant: Mark G. Currie

Inventor： Mark G. Currie

IPC: A61K31/785 ,  A61K31/575 ,  A61K31/4178 ,  A61K31/336 ,  A61K31/738 ,  A61P1/04 ,  A61P11/00

CPC classification number: A61K31/785 ,  A61K31/56 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed herein are novel compositions and methods for treating or preventing GI tract disorders and/or GERD-related respiratory disorders as well as protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, γ-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.

Abstract translation: 本文公开了用于治疗或预防胃肠道疾病和/或GERD相关呼吸障碍以及保护分层鳞状上皮免受有害物质损伤的新型组合物和方法。 所述方法通常包括向有需要的患者施用治疗有效量的包含至少一种胆汁酸多价螯合剂的药物组合物，其单独或与至少一种质子泵抑制剂组合，以及任选的一种或多种选自抗酸剂，组胺 H2-受体拮抗剂，γ-氨基丁酸-b（GABA-B）激动剂，GABA-B激动剂的前药和蛋白酶抑制剂。

公开(公告)号：US20110124583A1

公开(公告)日：2011-05-26

申请号：US12754138

申请日：2010-04-05

Applicant: Mark G. Currie ,  Shalina Mahajan-Miklos ,  Thea Norman ,  G. Todd Milne

Inventor： Mark G. Currie ,  Shalina Mahajan-Miklos ,  Thea Norman ,  G. Todd Milne

IPC: A61K38/10 ,  C07K7/00 ,  A61P1/00

CPC classification number: C07K7/08 ,  A61K38/00 ,  C07K14/245

Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

Abstract translation: 本发明的特征在于用于治疗IBS和其他胃肠道疾病和病症（例如胃肠蠕动障碍，功能性胃肠道疾病，胃食管反流病（GERD），克罗恩病，溃疡性结肠炎，炎性肠病，功能性胃灼热，消化不良（ 包括功能性消化不良或非溃疡性消化不良），胃轻瘫，慢性肠假性梗阻（或结肠假性梗阻）以及与便秘相关的疾病和病症，例如与使用阿片类止痛药相关的便秘，手术后便秘和便秘​​相关 与使用活化鸟苷酸环化酶C（GC-C）受体的肽和其他试剂的神经性疾病以及其它病症和病症。

公开(公告)号：US20090305993A1

公开(公告)日：2009-12-10

申请号：US12280376

申请日：2007-02-26

Applicant: Mark G. Currie

Inventor： Mark G. Currie

IPC: A61K38/10 ,  C07K7/08

CPC classification number: A61K31/56 ,  A61K38/10 ,  C07K7/08 ,  A61K2300/00

Abstract: Pharmaceutical compositions comprising certain peptides that are capable of activating the guanylate-cyclase C (GC-C) receptor are described as are the peptides and method for using the peptides and pharmaceutical compositions for treating gastrointestinal disorders and other disorder.

Abstract translation: 描述能够激活鸟苷酸环化酶C（GC-C）受体的某些肽的药物组合物是用于治疗胃肠道疾病和其它病症的肽和药物组合物的肽和方法。

公开(公告)号：US20090264653A1

公开(公告)日：2009-10-22

申请号：US12097616

申请日：2006-12-18

Applicant: Wilmin Bartolini ,  Brian M Cali ,  Barbara Chen ,  Yueh-Tyng Chien ,  Mark G. Currie ,  G. Todd Milne ,  James Philip Pearson ,  John Jeffrey Talley ,  Jane Yang ,  Craig Zimmerman ,  Charles Kim ,  Kevin Sprott ,  Timothy Barden ,  Regina Lundigran ,  Ara Mermerian

Inventor： Wilmin Bartolini ,  Brian M Cali ,  Barbara Chen ,  Yueh-Tyng Chien ,  Mark G. Currie ,  G. Todd Milne ,  James Philip Pearson ,  John Jeffrey Talley ,  Jane Yang ,  Craig Zimmerman ,  Charles Kim ,  Kevin Sprott ,  Timothy Barden ,  Regina Lundigran ,  Ara Mermerian

IPC: C07D413/14 ,  C07D209/04 ,  C07D235/00 ,  C07D403/04 ,  C07D215/02 ,  C07D471/02

CPC classification number: C07D209/42 ,  C07D209/30 ,  C07D401/06 ,  C07D409/06 ,  C07D417/06

Abstract: Indoles that have activity as inhibitors of FAAH are described as are indoles and indole derivatives that have activity as inhibitors of DAO.

Abstract translation: 具有作为FAAH抑制剂活性的吲哚被描述为具有作为DAO抑制剂的活性的吲哚和吲哚衍生物。